Accessibility Menu
Enliven Therapeutics logo

Enliven Therapeutics(NASDAQ) ELVN

Market Cap$4.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)+144%
5 Year+221%
1 Year+191%
1 Month+12%
$58.20
+0.24%
+0.14Today
Enliven Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 58.062026-08-13
Enliven Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.67%USD 60.272026-08-06
1 month+12.24%USD 51.732026-07-14
3 month+40.45%USD 41.342026-05-15
Year to date+277.01%USD 15.402025-12-31
1 year+190.52%USD 19.992025-08-13
3 year+252.95%USD 16.452023-08-14
5 year+221.13%USD 18.082021-08-13
Since inception+144.46%USD 23.752023-02-24

Enliven Therapeutics Financials at a Glance

Market Cap

$4.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$105.93M

EPS (TTM)

-$1.67

P/E Ratio

-34.80

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$58.20

Volume

105,947.457

Open

$57.67

Previous Close

$58.06

Daily Range

$56.69 - $58.22

52-Week Range

$14.79 - $62.32

Estimated Earnings Date

Nov 11, 2026

ELVN News

SellAlert-Green.png

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

Jonathan PoncianoJun 27, 2026
SellAlert-Red.png

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally

Jonathan PoncianoJun 27, 2026
Insider.png

Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?

Brendan CoffeyJun 24, 2026
SellAlert-Green.png

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.

Robert IzquierdoJun 1, 2026
f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Jonathan PoncianoMay 13, 2026
SellAlert-Red.png

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Cory RenauerMar 28, 2026
SellAlert-Purple.png

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Adé HennisFeb 1, 2026
Foolcom-Featured.png

Enliven Posts Loss Beat and Cash Surge

Motley Fool Markets TeamAug 13, 2025

ELVN: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Enliven Therapeutics

Enliven makes precision cancer drugs to help patients live longer and better. These small-molecule medicines target specific proteins that cause cancer cells to grow. The company currently focuses on helping adults with a specific type of blood cancer.

Fighting Cancer with Precision

  • ELVN-001: Targeted drug designed to block BCR-ABL, a protein that causes chronic myeloid leukemia, a slow-growing blood cancer.
  • Pipeline Programs: Early-stage research projects focused on finding new ways to stop cancer cells from multiplying using chemistry.
  • Strategic Assets: Contractual rights to receive payments if previously sold products reach specific commercial or development milestones.

Building the Business

  • Merged with Former Enliven on February 23, 2023, to form the current clinical-stage organization.
  • Raised $90 million through a private placement of stock and warrants on March 21, 2024.
  • Generated $230 million in gross proceeds from an underwritten public offering on June 16, 2025.
  • Secured a new headquarters in Burlingame, California, with a lease beginning in June 2026 to support expansion.

What Makes Enliven Different?

Enliven uses a discovery process that combines deep biological insights with specific chemistry to target validated disease markers. This approach aims to create therapies that are more effective and safer than existing treatment options.

Focus on the Numbers

  • Net loss narrowed to $23.6 million in Q1 2026, an improvement of 17.2% from Q1 2025.
  • Operating expenses reached $27.8 million in Q1 2026, down 12.2% from $31.7 million in Q1 2025.
  • Cash and marketable securities totaled $452.4 million as of March 31, 2026.
  • Interest income rose to $4.2 million in Q1 2026, up from $3.2 million in Q1 2025.

The Path Forward

Enliven has evolved into a well-capitalized clinical-stage company by focusing on specific, high-potential cancer treatments. Its recent consolidation of resources onto a lead candidate reflects a disciplined approach to drug development.

AI Generated • May 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

67

CEO

Richard A. Fair, MBA

Website

www.enliventherapeutics.com

Headquarters

Boulder, CO 80301, US

ELVN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-18.55%

Return on Capital

-26.01%

Return on Assets

-11.64%

Earnings Yield

-2.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

73.27M

Volume

105.95K

Avg. Volume

1.41M

Financials (TTM)

Gross Profit

-$60.00K

Operating Income

-$124.41M

EBITDA

-$105.81M

Operating Cash Flow

-$66.94M

Capital Expenditure

-$98.00K

Free Cash Flow

-$67.04M

Cash & ST Invst.

$895.16M

Total Debt

$1.51M

Enliven Therapeutics Performance Analysis

Enliven Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Enliven Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Enliven Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -12.0512.4%
20232023-12-31USD -2.01-83.3%
20242024-12-31USD -1.89-6.1%
20252025-12-31USD -1.83-3.2%
Enliven Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3034.7%
Q42025-12-31-40.6%
Q12026-03-3115.6%
Q22026-06-30-28.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$69.74M

N/A

Employees

61

N/A

Net Income

-$32.49M

-28.2%

EBITDA

-$32.49M

-28.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$895.16M

+82.5%

Total Debt

$1.51M

+160.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$913.00K

+347.5%

Short Term Debt

$597.00K

+58.8%

Return on Assets

-11.64%

N/A

Return on Invested Capital

-13.88%

N/A

Free Cash Flow

-$18.63M

-8.3%

Operating Cash Flow

-$18.53M

-8.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RLAYRelay Therapeutics, Inc.
$19.82-0.55%
ATAIAtai Beckley Inc.
$7.26+0.07%
PGENPrecigen, Inc.
$6.23-4.08%
NKTRNektar Therapeutics
$74.77-1.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.26+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.63-0.00%
ONDSOndas
$9.54+0.07%
INTCIntel
$103.23-0.01%

Questions About ELVN

What is the current price of Enliven Therapeutics?

Enliven Therapeutics is trading at $58.15 per share.

What is the 52-week range for Enliven Therapeutics?

Over the past 52 weeks, Enliven Therapeutics has traded between $14.79 and $62.32.

How much debt does Enliven Therapeutics have?

As of the most recent reporting period, Enliven Therapeutics reported total debt of $1.51M.

How much cash does Enliven Therapeutics have on hand?

Enliven Therapeutics reported $135.51M in cash and cash equivalents in its most recent financial results.

What is Enliven Therapeutics’s dividend yield?

Enliven Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services